Naučme se jednat s dětmi léčenými pro zhoubný nádor jako s ostatními! Vyhněme se přehnanému soucitu a zbytečným rozpakům! Malí pacienti si nezaslouží odtažitý přístup, nýbrž náš obdiv a úctu za statečný boj s těžkým osudem! Pomáhejme onkologicky nemocným dětem a jejich rodinám pod projektem MŮJ NOVÝ ŽIVOT!

MUDr. Lucie Cingrošová

Onkologie. 2013:7(2):59  

Maligní melanom - slovo úvodem

Viera Bajčiová

Onkologie. 2013:7(2):64  

Current therapy of advanced metastatic malignant melanoma

Radek Lakomý, Alexandr Poprach, Renata Koukalová

Onkologie. 2013:7(2):65-68  

Malignant melanoma is the most aggressive type of skin cancer. The incidence of melanoma is increasing faster than most other cancers and affects a high proportion of younger adults. The standard treatment with chemotherapy or biochemotherapy has not been able to significantly improve survival. The recent advances in immunology and molecular biology of melanoma have discovered several potencial therapeutic targets and helped to develop new promising drugs. Ipilimumab (anti-CTLA-4 antibody) and vemurafenib (the selective BRAF inhibitor) have demonstrated improved overall survival compared with chemotherapy in randomized trials. These agents...

Malignant melanoma in children and adolescents

Viera Bajčiová

Onkologie. 2013:7(2):69-73  

Melanoma is a rare malignancy in the pediatric population, but its incidence has risen very rapidly, specially in adolescent girls. We are presenting review of the current clinical and biological features of pediatric melanoma and problems with its diagnosis and management. Despite the differences between pediatric and adult melanoma survival rates are very similar. Age specific pediatric clinical studies are essential for management of metastatic pediatric malignant melanoma. Prevention and erly detection are also the point of interest.

Fluorescence in situ hybridization in diagnostics melanocytic lesions

Jana Dvořáčková, Jana Žmolíková, Jan Mužík, Magdalena Uvírová

Onkologie. 2013:7(2):74-77  

Melanocytic lesions exhibit significant morphological heterogenity, making their diagnosis difficult, although both sophisticated histopathological and immunohistochemical methods are used. The introduction of molecular genetic method flourescence in situ hybridization (FISH) has contributed significantly to the diagnosing of melanocytic lesions. Between 2008 and 2012, we studied a total of 160 samples of different types of melanocytic lesions, including 44 nevi and 116 melanomas, using a four-color probe mix for CCND1, RREB1 and MYB genes and for the centromere of chromosome 6. A positive result was found in 116 melenoma samples (72.5 %) and...

Histological changes in malignant melanoma of the eye following radiotherapy with CyberKnife

Jana Dvořáčková, Jirka Mačák, Petr Mašek, David Feltl, Jana Žmolíková

Onkologie. 2013:7(2):78-82  

Radiosurgery with CyberKnife is used in the treatment of uveal melanomas in some cases. Histological and immunohistological changes in tumour tissue following treatment have been addressed by relatively few authors. This paper presents the results of investigations of two such cases. Enucleation of the eye was performed for painful glaucoma in both patients. Patient 1 had a recurrent melanoma treated with a Gamma Knife ten years ago. Due to slight progression in the melanoma site, treatment with CyberKnife was used with total doses of 45 Gy in 3 fractions. Some five months following eye irradiation, there was regression of the recurrent tumour...

Non-surgical treatment of metastatic renal cell carcinoma

Milada Zemanová

Onkologie. 2013:7(2):83-87  

The treatment of advanced and metastatic renal cell cancer is based on systemic therapy in combination with cytoreductive local approaches. Cytokines, used in the past, may currently be beneficial for patients in a good prognostic group, but molecularly targeted biological treatment, mainly directed at key points of the defective VHL/HIF pathway, showed significantly better efficacy in patients of all prognostic groups with prolonged survival compared to interferon alpha. Currently tyrosinekinase receptor inhibitors for angiogenic growth factors, sorafenib, sunitinib and pazopanib, monoclonal antibody neutralizing vascular endothelial growth...

Erlotinib in the treatment of advanced pancreatic cancer

Petr Karásek, Beatrix Bencsiková, Jiří Navrátil

Onkologie. 2013:7(2):88-89  

Pancreatic cancer belongs to the most malignant gastrointestinal tumors. Efforts to improve survival outcomes with gemcitabine-based combination chemotherapy regimens have been largely disappointing. Among targeted therapies only the EGFR tyrosine kinase inhibitor erlotinib has shown activity, but clinically relevant in patients developing skin rash.

Gastric cancer and trastuzumab: first biologic therapy in gastric cancer

Andrea Jurečková, Štěpán Tuček

Onkologie. 2013:7(2):97-98  

Gastric cancer remains difficult to cure and has a relatively poor prognosis. Current multimodal therapeutic approaches, including chemotherapy, have shown some benefit for the patients, yet have their limitations. Thus, we are in need of developing new treatment options, preferably in the field of targeted therapies. The article reviews therapy with focus on trastuzumab in patients with human epidermal growth factor receptor 2 (HER2+) positive gastric cancer.

Quality of life of a patient treated with cabazitaxel for metastatic prostate cancer

Jana Katolická

Onkologie. 2013:7(2):90-91  

The treatment for metastatic prostate cancer is only of palliative nature. Chemotherapy with docetaxel in the first line and with cabazitaxel in the second line of treatment for castration-resistant prostate cancer has a prolonged survival benefit. Oncological treatment also significantly affects the quality of life that includes not only the sense of physical health and physical performance status, but also mental well-being, social functioning, and family relationships.

The Coincidence of Renal Cell Carcinoma and Gaucher Disease

Štěpán Tuček, Jiří Tomášek

Onkologie. 2013:7(2):92-94  

The article describes a case of a patient with a very rare benign storage disease appearing in skelet that was imitating a metastatic spread of an advanced renal cell carcinoma. Even a very unlikely case of coincidence of rare diseases can be real in the clinical practice. Such a situation can lead to an erroneous diagnostic workup. The Gaucher disease is a disease with various possible forms. Some as the juvenile form can be serious with severe developmental limitations- and some as the adult form can rather be with lighter symptoms or inapparent at all. The diagnostics and treatment have developed a lot over the past years. The highest incidence...

Cetuximab administered concomitantly with radiotherapy in a patient with locally advanced

Markéta Pospíšková, Milan Kohoutek

Onkologie. 2013:7(2):95-96  

p16-negative cancer of the soft palate Worldwide, head and neck tumours are among cancers with an increasing incidence. The main aetiological factors determining their development are smoking, alcohol abuse, and recently detected HPV. Two thirds of patients present in an advanced stage and up to a third of them have numerous comorbidities. A multidisciplinary approach is of utmost importance in the treatment. The standard treatment according to NCCN is concomitant chemoradiotherapy with a platinum derivative (category 1) or radiotherapy concomitantly with biological therapy with cetuximab, or surgical approach, followed by, according to histology,...

Prague ONCO 2013 - viděno z publika

Lenka Ostřížková

Onkologie. 2013:7(2):100  

Prague Onco 2013 - významný host

Onkologie. 2013:7(2):102